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Summary.-Leucocyte migration inhibition by autologous breast tumour cell
fractions was mediated by a soluble factor synthesized and released by mononuclear
leucocytes and active against migrating granulocytes. This mechanism is similar
to that previously described in respect to cell-mediated sensitivity to microbial
antigens. Alternative mechanisms involving directly reactive granulocytes or
cytophilic antibodies were rarely operative in the migration tests.
THE leucocyte migration test (LMT)
of S0borg and Bendixen (1967) has been
successfully employed in studies of tu-
mour-directedimmuneresponsesinpatients
with breast cancer (Andersen et al., 1970;
Cochran et al., 1974; Jones and Turnbull,
1974, 1975; McCoy et al., 1974); malignant
melanoma (Cochran, Jehn and Gothoskar,
1972; McCoy et al., 1975); hypernephroma
(Kjaer, 1974); and various other tumours
(Wolberg, 1971; Segall et al., 1972).
Significant discrimination between pa-
tients and controls was achieved, and
the possibility exists that this simple
and reproducible assay might be of
considerable value in the clinical assess-
ment ofpatients with cancer.
Mechanisms involved in LMT have
mainly been studied inrespect ofsensitiza-
tion by bacterial, fungal and viral anti-
gens, and it was thought that in most
cases inhibition was mediated by a soluble
factor (leucocyte inhibitory factor, LIF)
released by sensitized lymphocytes in
the presence of specific antigen (S0borg,
1969; Clausen, 1973; Rocklin, 1974;
Hoffman et al., 1975). Alternative mech-
anisms thought to be operative under
certain circumstances included reactions
between antigens and cytophilic anti-
bodies on the surface of leucocytes
(Packalen and Wasserman, 1971; Rocklin,
1974) and the direct action of antigen
on sensitized granulocytes (Senyk and
Hadley, 1973). The present study pro-
vides evidence that leucocyte migration
inhibition by particulate breast tumour
cell fractions is mediated by mononuclear
cells and is probably a manifestation of
cellular immunity.
MATERIALS AND METHODS
Patients.-The patients studied form part
of an on-going therapeutic survey comparing
simple mastectomy for Stage I or Stage II
breast cancer with simple mastectomy plus
radical radiotherapy. The control group
consisted of healthy hospital workers, hos-
pital in-patients with malignancies of organs
other than breast and patients with benign
breast disease.
Preparation of tumour cell fractions.-The
preparation of particulate extracts from
malignant breast tumours has been fully
described elsewhere (Jones and Turnbull,
1975). Briefly, tissue obtained at operation
was minced and disrupted using a dounce-
type hand homogenizer and the homogenate
centrifuged at 1000 g to remove nuclei.
The supernatant (extract) was also further
centrifuged at 3000 g and the sediment
(3000 g fraction) retained.
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Separation of leucocytes -25-ml samples
of blood were taken into 20 units/ml pre-
servative-free heparin. 6-ml aliquots were
layered on to 4 ml Ficoll-Triosil (FT),
sp. gr. 1 07-1 08, and erythrocytes allowed
to sediment for 60 min at room temperature.
The upper layer of leucocyte-rich plasma
was centrifuged at 350 g for 5 min and the
cell pellet washed 3 times in tissue culture
medium TC 199 supplemented with 13 mM
NaHCO3, 20 mM HEPES buffer, 200 ,ug/ml
L-glutamine, 300 i.u./ml penicillin and 300
,ug/ml streptomycin.
To separate mononuclear leucocytes and
granulocytes, leucocyte-rich plasmas were
diluted with an equal volume of TC 199,
layered on to further aliquots of FT and
centrifuged at 400 g for 40 min. The white
band of cells at the plasma-FT interface
(mononuclears) and the cell pellet (granulo-
cytes) were collected and washed 3 times in
TC 199.
Cell migration tests.-Migration inhibition
tests were performed using a semi-micro
method developed specifically to utilize
minimal quantities of tumour cell fractions
and which was previously shown to give
a high degree of reproducibility (Jones and
Turnbull, 1975). Tumour extracts at 100
and 200 jg/ml in TC 199 + 10% foetal
calf serum (FCS), tumour 3000 g fraction
at 100 and 200 Hg/ml, and control medium
TC 199 + 10% FCS without antigen were
added to consecutive wells of the Sterilin
migration chamber. Three heat-sealed capil-
laries, each containing 6 x 105 cells, were
carefully positioned within each well, cover-
slips added and migration allowed to proceed
for 18 h at 37°C. Migration areas were
measured by projection microscopy and
planimetry and migration indices (MI) for
each dilution of antigen calculated as
follows:
Mean migration area in
MI- =tumour cell fraction
-Mean migration area in control medium
In a small number of cases, the effect
of puromycin on leucocyte migration inhibi-
tion was examined, when protein synthesis
inhibitor was included in the migration
medium at a concentration of 10 jug/ml.
Indirect assay for LIF.-Mononuclear
leucocytes from control subjects or from
patients with breast cancer, 2 x 106/ml, were
incubated for 3 days at 37°C in the presence
2
of 200 ,ug/ml tumour extract or 3000 g
fraction, or in control medium TC 199 + 100%
FCS, the culture volume being 0-8 ml.
Culture supernatants were obtained by
centrifugation at 1000 g for 10 min, and
granulocytes from control subjects without
breast cancer were used as migrating in-
dicator cells for LIF produced during
culture.
Cytophilic antibodies.-The presence of
humoral factors able to passively sensitize
control leucocytes was examined using the
method of Amos et al. (1967). Plasmas were
obtained in the course of isolating leucocytes
from whole blood; 20 samples came from
breast cancer patients who had given
positive results in direct LMTs against
autologous tumour fractions, while 6 were
from control subjects. Thrice washed leuco-
cytes or separated granulocytes were in-
cubated for 1 h at room temperature in
4 ml TC 199 + 10% plasma. Cells were
recovered by centrifugation, carefully washed
3 times in TC 199 and dispensed into capil-
laries for migration tests against tumour
extracts and 3000 g fractions.
RESULTS
Separated cell populations
Microscopic examination of Jenner-
Giemsa-stained smearsrevealedthatmono-
nuclear cell preparations contained 87-95
(mean 89) Qo lymphocytes, 3-12 (mean
10) 00 monocytes and 0-3 (mean 1) %
granulocytes. Granulocyte preparations
contained 0-5 (mean 2.5) 00 contaminating
lymphocytes.
Control MI values
In migration studies employing leuco-
cytes from 58 control subjects and
fractions from over 100 tumours, 2226
MI values were normally distributed
about a mean of 0-975, standard deviation
0-085. The 9500 confidence limits were
therefore 0-805-1-145 and values <0-80
and >1-15 were considered to indicate
migration inhibition and enhancement
respectivelv.I
Indirect assay for LIF
Culture supernatants obtained when
separated mononuclear cells from 10
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control subjects were incubated in the
presence of cell fractions from 24 breast
tumours failed to inhibit the migration
of control granulocytes (mean MI 0*97,
range 0-82-1F13). Similar supernatants
obtained by incubating mononuclear cells
from breast cancer patients with auto-
logous tumour extracts were inhibitory
in 4/22 (18%) cases, with autologous
3000 g fractions giving 6/24 (25%) positive
tests. In all, 10/24 (42%) patients re-
sponded to extract and/or 3000 g fraction
by the indirect assay (P < 0.01, x2 with
Yates' correction). When the same pa-
tients were examined by the direct
LMT, 6/22 (27%) responded to autologous
extract, 7/24 (29%) to autologous 3000 g
fraction and 11/24 (46%) to at least
one of the preparations. Agreement be-
tween the two methods occurred in
41/46 (89%) tests (P < 0.0001, x2 test;
Table I).
TABLEI1. Effect ofPuromycin on Leuco-
cyte Migration Inhibition. In All but
One Case, the Response to Autologous
Breast Tumour Cell Fractions was Abo-
lished by Puromycin Included in the



















(mean 1-04, range 0.91-1.29) than when
it was omitted (mean 0 93, range 0-82-
1.09). As shown in Table II, 7/10 breast
cancer patients gave leucocyte migration
inhibition by autologous extract and/or
3000g fraction in the absence of puro-
mycin, while only 1/10 patients remained
reactive in the presence of this agent
(P < 0.05, X2 with Yates' correction).
TABLE I.-Comparison of Direct (Leuco-
cyte Migration Inhibition by Autologous
Breast Tumour Fractions included in
the Migration Medium) and Indirect
(Granulocyte Migration Inhibition by
Factors produced in Mononuclear Cell
Cultures with Autologous Tumour Frac-
tions) Assays for LIF. Agreement be-
tween the Two Methods Occurred in


















Addition of puromycin to the leucocyte
migration system
Migration areas in medium containing
10 clg/ml puromycin were reduced on
average by 40% compared with migration
areas in medium without added protein
synthesis inhibitor. Control MIs (5 sub-
jects tested against fractions from 10
tumours) were close to unity whether or
not this agent was included in the migra-
tion medium, although control MIs were
higher when puromycin was included
Comparison of leucocyte and granulocyte
migration inhibition
Leucocytes and separated granulo-
cytes from 5 control subjects were used
as migrating cells in tests against extracts
and 3000 g fractions from 10 tumours.
The mean MI for leucocytes was 0-98,
range 0-84-1-13, while for granulocytes
the mean was 0-95, range 0-84-1-16.
Results shown in Table III indicated
that although granulocytes from breast
cancer patients were contaminated by
up to 5% lymphocytes, migration was
not inhibited in any of the tests against
autologous breast tumour cell fractions.
This was in contrast to the finding that
leucocytes from the same patients were
inhibited by autologous extract and/or
3000 g fraction in 5/10 cases (P < 0-05,
x2 with Yates' correction). In view of
the possibility that granulocyte response
to LIF produced by contaminating lym-
phocytes, or the direct response of sen-
sitized granulocytes to antigen, might be
impaired due to additional cell separation
procedures, isolated mononuclears and
granulocytes were admixed to contain
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TABLE III. CoMparison of Leucocyte and Granulocyte Migration Inhibition. Granulo-
cytes Containing 500 Contaminating Mononuclear Cells were Non-responsive in
Migration Tests (P < 0.05), while the Addition of Approximately 300O Mononuclear





Granulocytes, 70% -i- mononuclears, 30%
b
a + to 3000 g
+ to extract fraction
1/10 (10%) 4/10 (40%)
0/10 0/10
1/5 (20%) 2/5 (40%)
2/5 (40%) 2/5 (40%)





TABLE IV. Failure ofPlasmasfrom LMT+ Breast Cancer Patients to Passively


















approximately 30 o lymphocytes. The
migration of these cells, and of leucocytes
from the same patients, were inhibited
in 2/5 cases (Table III).
Cytophilic antibodies
When control leucocytes or granulo-
cytes were incubated with plasmas from
healthy individuals before performing
migration tests against breast tumour
extracts and 3000 g fractions, MI values
were within the normal range in all
cases (0583-1b01, mean 0-91, for leuco-
cytes; 0589-1b09, mean 0 99, for granulo-
cytes). The migration of control leuco-
cytes was inhibited after incubation with
plasmas from only 4/20 LMT+ breast
cancer patients, and although 2/20 plasmas
caused enhanced migration of granulo-
cytes, inhibition of these cells was not
observed (Table IV).
DISCUSSION
Leucocyte migration inhibition by
breast tumour cell fractions was appa-
rently not mediated by directly reactive
granulocytes, nor in the majority of
cases were cytophilic antibodies involved
in the in vitro response. Addition of
puromycin to LMTs suppressed inhibition,
suggesting that active protein synthesis
occurred in the course of the response
to antigen. Mononuclear leucocytes, the
majority of which were lymphocytes,
from many of the patients studied,
released a soluble factor into the culture
medium when incubated with autologous
tumour fractions, and this factor was
able to inhibit the migration of granulo-
cytes from control subjects without breast
cancer. Thus the primary mechanism of
leucocyte migration inhibition by in-
soluble tumour cell fractions was thought
to be similar to that previously described
in studies of delayed hypersensitivity to
soluble microbial antigens.
While lymphokine production is
thought to be a manifestation of the
cellular immune system, production of
macrophage inhibitory factor (Rocklin et
al., 1974), chemotactic factor (Altman
and Mackler, 1974) and interferon (Ep-
stein, Kreth and Herzenberg, 1974) by
B- as well as T-lymphocytes has recently
been reported. Fimmel (1975) showed
that E rosette-forming cells were required
for the production of LIF in response
to E. coli somatic antigen, PPD and
influenza virus antigen, but further studies
are clearly required to determine the
lymphocyte subpopulation active in leuco-
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cyte migration inhibition by particulate
tumour-derived antigens.
We have shown that granulocyte
preparations containing as many as 5%0
lymphocytes were not inhibited by auto-
logous breast tumour fractions, while the
addition of approximately 30%0 lympho-
cytes restored reactivity. Fimmel (1975)
obtained inhibition when granulocyte pre-
parations containing less than 2 0 lympho-
cytes were allowed to migrate in the
presence of specific microbial antigens,
but further passages through Ficoll-
Hypaque columns reduced the number
of contaminating lymphocytes to less
than 0.10% and abrogated migration
inhibition. Thus it appeared that the
LMT response to tumour-derived antigens
requires higher numbers of lymphocytes
in the migrating cell population than
were needed for the response to microbial
antigens. This possibly reflects the in-
herent weakness of the tumour-directed
response and in particular suggests that
a relatively low proportion of peripherally
circulating lymphocytes are committed to
anti-tumour activities. In this respect
it is interesting to note that Ellis et al.
(1975) observed a higher proportion of
LMT+ responses to breast tumour anti-
gens using cells from the tumour-draining
lymph node rather than peripheral blood
leucocytes, presumably due to localization
of tumour-reactive lymphocytes in the
former population.
Although the tumour-directed LMT
is able to discriminate successfully be-
tween patient and control groups on a
statistical basis, it has not been possible
to demonstrate sufficiently high numbers
of positive results in patients with early
breast cancer for the technique to be
developed as a diagnostic procedure.
Various modifications of the test itself
have failed to overcome this problem,
though it is possible that refinement
of antigen preparation procedures might
yield further progress. Early studies em-
ployed tumour homogenates partially
clarified by low speed centrifugation (ex-
tracts, Andersen et al., 1970) and we
have shown that the additional use
of a 3000 g fraction rich in large mem-
branous cell fragments increases the rate
of positive results (Jones and Turnbull,
1975). McCoy et al. (1974) have improved
still further on our rate of approximately
5000 patients positive at 7 days after
simple mastectomy: using 3M KCI ex-
tracts of breast tumours, significant leuco-
cyte migration inhibition was obtained
in 20/26 (770o) pre- or immediately post-
surgery breast cancer patients. Possibly
the higher rate of positives was due to
the fact that soluble antigens could be
used at higher concentrations without
causing non-specific inhibition of control
leucocyte migration.
It was previously shown that serial
postoperative measurements of tumour-
directed leucocyte migration inhibition in
breast cancer patients may be ofrelevance
to the understanding of the complex
host-tumour interrelationship and may
provide information of clinical significance
(Jones and Turnbull, 1975; Jones et
al., 1976). This paper has tried to con-
firm that the in vitro response to particu-
late tumour-derived antigenic material is
mediated by cellular immune mechanisms
and thus permit interpretation of the
clinical correlations observed in breast
cancer patients.
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